| Literature DB >> 33514855 |
Liang-Yun Li1,2, Jun-Fa Yang3, Fan Rong1,2,4, Zhi-Pan Luo1,2,5, Shuang Hu1,2, Hui Fang6, Ying Wu5, Rui Yao1,2,3, Wei-Hao Kong5, Xiao-Wen Feng1,2, Bang-Jie Chen7, Jun Li1,2, Tao Xu8,9.
Abstract
Zinc finger E-box-binding homeobox 1 (ZEB1), a functional protein of zinc finger family, was aberrant expressed in many kinds of liver disease including hepatic fibrosis and Hepatitis C virus. Bioinformatics results showed that ZEB1 was abnormally expressed in HCC tissues. However, to date, the potential regulatory role and molecular mechanisms of ZEB1 are still unclear in the occurrence and development of HCC. This study demonstrated that the expression level of ZEB1 was significantly elevated both in liver tissues of HCC patients and cell lines (HepG2 and SMMC-7721 cells). Moreover, ZEB1 could promote the proliferation, migration, and invasion of HCC cells. On the downstream regulation mechanism, ZEB1 could activate the Wnt/β-catenin signaling pathway by upregulating the protein expression levels of β-catenin, c-Myc, and cyclin D1. Novel studies showed that miR-708 particularly targeted ZEB1 3'-UTR regions and inhibited the HCC cell proliferation, migration, and invasion. Furthermore, results of nude mice experiments of HCC model indicated that miR-708 could inhibit tumor growth and xenograft metastasis model was established to validate that miR-708 could inhibit HCC cell metastasis through tail-vein injection in vivo. Together, the study suggested that ZEB1 modulated by miR-708 might be a potential therapeutic target for HCC therapy.Entities:
Keywords: HCC; Wnt/β-catenin; ZEB1; miR-708; xenograft metastasis
Mesh:
Substances:
Year: 2021 PMID: 33514855 PMCID: PMC8463676 DOI: 10.1038/s41401-020-00575-3
Source DB: PubMed Journal: Acta Pharmacol Sin ISSN: 1671-4083 Impact factor: 7.169